SCHEMBL8183005

SCHEMBL8183005

O=C(O)Cc1cn(Cc2ccc(Oc3ccc(Cl)c(Cl)c3)cc2)c2ccccc12

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.62
▸ LMNA P02545 3/20 0.62
▸ ICMT O60725 2/20 0.53
▸ PPARD Q03181 4/20 0.52
▸ PPARG P37231 3/20 0.52
▸ PPARA Q07869 3/20 0.52
▸ MCL1 Q07820 3/20 0.51
▸ PLA2G2A P14555 3/20 0.48
▸ HTT P42858 1/20 0.47
▸ NCOA1 Q15788 1/20 0.47
▸ NCOA3 Q9Y6Q9 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ CDC25A P30304 1/20 0.46
▸ USP2 O75604 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8172460 0.93 LMNA (0.68) ALDH1A1LMNAICMTPPARDPPARG
SCHEMBL13931026 0.90 ALDH1A1 (0.65) ALDH1A1LMNAICMTPPARDPPARG
SCHEMBL8178903 0.89 ALDH1A1 (0.67) ALDH1A1LMNAICMTPPARDPPARG
SCHEMBL8167182 0.88 LMNA (0.74) ALDH1A1LMNAICMTPPARDPPARG
SCHEMBL13931422 0.88 LMNA (0.67) ALDH1A1LMNAICMTPPARDPPARG
SCHEMBL8178890 0.87 ICMT (0.47) ALDH1A1LMNAICMTMCL1PLA2G2A
SCHEMBL8175344 0.86 LMNA (0.65) ALDH1A1LMNAICMTPPARDPPARG
SCHEMBL8181417 0.86 ALDH1A1 (0.61) ALDH1A1LMNAICMTPPARDPPARG
SCHEMBL8178901 0.86 ALDH1A1 (0.60) ALDH1A1LMNAICMTPPARDPPARG
SCHEMBL8182990 0.85 PPARG (0.62) ALDH1A1LMNAICMTPPARDPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-02-19 — — US disclosed
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-02-19 — — US disclosed
WO-2008100867-A2 NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2008-08-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION EIF2AK2, HAVCR2, HCCS ALDH1A1 1836/4885LMNA 2969/4885ICMT 2415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback